drugset / Trial / NCT02581501
Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells.
Timeline
- Start
- 2016-02
- Primary completion
- 2016-12
- Completion
- 2016-12
Outcome
Outcome not reported
Stopped (Enrollment): “Due to no enrollment, Celgene (sponsor) withdrew funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abraxane | Small molecule | 75 mg/m2 | — |
| Subject | Abraxane | Small molecule | 100 mg/m2 | — |
| Subject | Abraxane | Small molecule | 125 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 500 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 600 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 750 mg/m2 | — |